People taking Ozempic for diabetes may be at risk of worsening symptoms of the disease
We specifically excluded studies that did not investigate the use of GLP-1 receptor agonists for weight loss in children and adolescents
For binary variables (such as clinical pregnancy rate and live - birth rate), the odds ratio (OR) and 95% confidence interval (CI) were used for pooled analysis
While we lack definitive RCT data, there is a strong physiological rationale and emerging real-world experience suggesting benefits from tapering doses (e.g., 15 12.5 10 2.5 mg) before stopping: Allows neurohormonal pathways to recalibrate gradually rather than abruptly Provides a window to stabilize lifestyle adjustments at each step May help identify a lowest effective maintenance dose that sustains satiety signals Reduces the shock of withdrawal, lowering the risk of rapid rebound Key takeaway: The narrative that all patients regain weight after GLP-1/GIP therapy overlooks an important nuance: regain has been observed when treatment is stopped suddenly at high doses
It also helps minimize headaches, stabilize energy levels, and support clearer thinkingthings that are often impacted during the early phases of GLP-1 treatment
If you are already on a program, consider trying our GLP-1 Daily Support supplement to ensure your body has the nutritional foundation it needs during your transformation
